Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in ...

If both genetic parents are Rh-negative, their children will be, too. The pregnant parent should have their blood type, including Rh factor, tested and antibody screening done if indicated as part of ...

In the rapidly evolving field of antibody drug discovery, the ability to efficiently characterize and screen antibodies and antibody drug conjugates (ADCs) is crucial for developing effective ...

Of the candidates that the San Diego-based company is now prioritizing for internal development, the most advanced is an anti-AXL antibody-drug conjugate called mecbotamab vedotin. BioAtla said ...

But promising results from a recent clinical trial suggest that broadly neutralizing antibody therapy (bNAbs) may be able to accomplish the next best thing. Data from the trial—a collaboration ...

Dr. James Hansen, a Yale Cancer Center researcher, and his team discovered that using an antibody related to lupus they can breach the tumor and trigger an immune response to fight it. He says ...

New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers VANCOUVER, British Columbia, March 25, 2025 (GLOBE ...

In the latest investment in the immunology space, Sanofi has agreed to a $600 million upfront payment to buy Dren Bio’s investigational bispecific antibody DR-0201 in a deal announced Thursday. The ...

In this review, we will summarize recent progress in the use of antibody-based or related strategies for targeting claudins in cancer treatment. We first describe pre-clinical studies that have ...

View Full Profile. Learn about our Editorial Policies. Scientists create monoclonal antibodies by cloning a single antibody-producing cell line. In contrast to polyclonal antibodies, monoclonals are ...